Xal competitive analysis

Explore patent oppositions filed by Xal against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 19, 2026
Patent NumberTitleApplicantOpposition Date
Connection Device With Mobile Command Device Comprising A Translating RodAAG STUCCHINov 18, 2026
Method For Treating Multiple SclerosisF HOFFMANN LA ROCHEAug 27, 2025
Anticancer CompositionsARAGON PHARMACEUTICALSJul 9, 2025
Tablets Comprising Glp-1 Agonist And Enteric CoatingNOVO NORDISKOct 17, 2024
Compositions Comprising A Delivery Agent And Preparation ThereofNOVO NORDISKJun 13, 2024
Solid Compositions Comprising A Glp-1 Agonist, A Salt Of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid And A LubricantNOVO NORDISKApr 19, 2024
Compositions Of Glp-1 Peptides And Preparation ThereofNOVO NORDISKMar 7, 2024
Treatment Regimen Utilizing Neratinib For Breast CancerWYETHNov 3, 2023
Compositions And Uses For Treating Multiple SclerosisBIOGEN IDEC MAJul 21, 2022
Composition Comprising Antibody That Binds To Domain Ii Of Her2 And Acidic Variants ThereofGENENTECHNov 8, 2021

Latest PTAB cases involving Xal

Discover the latest PTAB cases involving Xal, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Xal with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 19, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
HEXAL976 - -
BIOGEN MA169 - 7
BOEHRINGER INGELHEIM4525689
NOVO NORDISK2313919